trending Market Intelligence /marketintelligence/en/news-insights/trending/2qixecajujhpujkxudwa8g2 content esgSubNav
In This List

Allergan exec responsible for leading Botox franchise joins Evolus


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Allergan exec responsible for leading Botox franchise joins Evolus

Irvine, Calif.-based Evolus Inc. said it appointed Michael Jafar as chief marketing officer.

Jafar, the former vice president of medical aesthetics at Allergan PLC, will join Evolus, which is looking to market a copycat version of Botox.

Botox is Allergan's blockbuster drug, which is used to fill wrinkles and treat migraine headaches.

Jafar led product development and market initiatives for the Botox Cosmetic, Juvederm, Kybella, Latisse and Natrelle franchises at Allergan.

"I am confident that Mike will have an immediate impact on our organization and bring a fresh perspective to our team as we further develop and execute our commercial strategy," Evolus President and CEO David Moatazedi said in a statement.

In May, the U.S. Food and Drug Administration rejected Evolus' application to market DWP-450 for wrinkles.

DWP-450, also known as prabotulinumtoxinA, is expected to compete with Botox. Evolus said it would work with the regulator to address the issues raised and expects to launch the treatment by spring 2019.